Influence of blood collection methods and long-term plasma storage on quorum-sensing peptide stability by Debunne, Nathan et al.
Influence of Blood Collection Methods and Long-Term Plasma
Storage on Quorum-Sensing Peptide Stability
Nathan Debunne,∥ Anton De Spiegeleer,∥ Dorian Depuydt, Yorick Janssens, Ameĺie Descamps,
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ABSTRACT: Finding adequate biomarkers for rapid and accurate
disease detection, prognosis, and therapy is increasingly important.
Quorum-sensing peptides are herein a new emerging group,
produced by bacteria, fungi, protozoa, and viruses, with blood
being the most straightforward sample type to detect/quantitate
them. However, detailed information about suitable blood sample
collection methods and storage conditions for measuring these
quorum-sensing peptides hampers further clinical research and development. Here, we first tested the time-dependent stability of a
set of chemically diverse quorum-sensing peptides, spiked in blood at different temperatures (4, 21, and 37 °C) in four different
ethylenediamine tetraacetic acid (EDTA)-containing plasma tubes (with different protein-stabilizing additives) over a period of up
to 7.5 h. Next, we determined the storage stability of these quorum-sensing peptides in plasma at different temperatures (4, −35, and
−80 °C). UPLC/MS−MS was used to selectively detect and quantify the spiked quorum-sensing peptides. The results of this study
indicate that a cost-effective tube, designed for traditional proteomics and stored at 4 °C, is the preferred collection condition when
quorum-sensing peptides need to be detected/quantified in human plasma. When the tubes are handled at room temperature (21
°C), a more specialized tube is required. Long-term storage of plasma samples, even under low-temperature conditions (−80 °C),
indicates rapid degradation of certain quorum-sensing peptides.
1. INTRODUCTION
Clinical diagnostics and therapeutics are moving from large
cohort-based approaches toward personal-based strategies,
thereby requiring adequate biomarkers. Because of its
accessibility and ease of downstream processing, human
blood is predominantly investigated and used for the
identification of suitable biomarkers. Different chemical classes
of possible blood biomarkers exist, e.g., proteins, circulating
DNA, microRNA, and small-molecular metabolites such as
organic acids.1−3 Recently, a growing interest is seen in
peptides as potential blood biomarkers.4,5 Peptides can be
considered as an intermediate class between small molecules
(metabolomics) and proteins (proteomics). They differ from
proteins not only because they are shorter (traditionally
considered below 50 amino acids) but also because of their less
complex three-dimensional structure.6 These different phys-
icochemical characteristics influence the biological behavior of
peptides. For example, peptides often show an increased renal
clearance and/or enzymatic degradation in vivo.7,8 They also
require different analytical methodologies compared to small
metabolites and large proteins. For example, the sample
preparation and chromatography for peptides are completely
different.9,10 Recently, a novel class of peptides, i.e., the
quorum-sensing peptides from bacterial, fungal, protozoal, and
viral origin, has been identified as an interesting group of
peptides, as they influence different types of host cells and
hence play a role in the health of the host.11−14
To date, only a few studies have investigated to some extent
the influence of some blood collection parameters and the
effects of long-term human plasma storage on peptide
stability.15−20 However, they investigated only one specific
peptide and/or one specific factor. None of the reported
studies investigated simultaneously the three critical variables
in blood collection (temperature, choice of stabilizing additive,
and time) on a broad range of peptides. Moreover, the
quorum-sensing peptides, with their specific peptide structure
and diversity,21 have never been investigated.
The aim of the present study was therefore to investigate the
influence of the blood collection method and long-term plasma
storage on quorum-sensing peptide stability. For the blood
collection experiments, time, temperature, and choice of
different protease/peptidase-inhibitor additives were simulta-
neously considered as variables. The optimal blood collection
method was then used to study the quorum-sensing peptide
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stability in plasma at different storage temperatures.
Quantitative ultraperformance liquid chromatography−mass
spectrometry (UPLC/MS−MS) was used to detect and
quantify the different quorum-sensing peptides, selected to
cover as much as possible the chemical quorum-sensing
peptide space. As such, the results of this study can be useful in
the research of clinical blood and plasma quorum-sensing
peptidomics.
2. RESULTS AND DISCUSSION
The human peptidome consists not only of cryptides, i.e.,
peptides formed by cleavage of endogeneous or food-derived
proteins, but also of small open reading frame (smORF)
encoded peptides (SEPs) and of peptides from our micro-
biome,22,23 including quorum-sensing peptides from bacteria,
fungi, and viruses.24−26 Recently, these microbiologically
derived peptides have been shown to interact with human
host cells.11−14 Consequently, their biological functionality
makes them possible biomarker candidates to be quantified in
biofluids like blood. In light of this emerging new group of
biomarkers, there is a need for suitable blood collection and
storage procedures to reliably measure them. To address this
question, we investigated three critical variables in parallel for
blood collection: temperature, choice of stabilizing additives
(i.e., tube type), and time. Four types of tubes were used, i.e., a
conventional ethylenediamine tetraacetic acid (EDTA)
plasma-sampling tube (EDTA), a conventional EDTA tube
with a protease-inhibitor cocktail from Sigma-Aldrich (EDTA
+), and two different plasma tubes from Becton Dickinson
with EDTA and proprietary human protease/peptidase
inhibitors (P100 and P800). Moreover, in contrast to some
other plasma peptidomic studies, we investigated the quorum-
sensing peptide stability also in blood, i.e., prior to
centrifugation of the blood sample for obtaining plasma. As
it is often not feasible to centrifuge the plasma tubes
immediately after blood withdrawal (e.g., physician or research
offices from which the blood samples have to be transported to
a separate laboratory for processing and analysis), the peptide
stability in blood before centrifugation is a time-critical step.
To rule out freeze−thaw effects, our blood collection stability
experiments were conducted on fresh samples, i.e., not frozen.
As peptidome analysis is, in most clinical situations, only
possible after plasma has been stored, the long-term storage in
plasma was also investigated. For this experiment, plasma from
the BD 100 tube, conferring the largest whole-blood peptide
stability (described in Section 2.1), was used. Long-term
storage at three temperatures that are common in clinical and
research settings (4, −35, and −80 °C) was compared. UPLC/
MS−MS was used for the detection and quantitation of the
peptides in all experiments, as this method enabled us to
achieve high selectivity combined with quantification charac-
teristics. Figure 1 shows a representative liquid chromatog-
raphy−mass spectrometry (LC−MS) chromatogram. Inherent
to our study design, the conclusions are focused on peptide
stability sensu stricto. This means that we did not take into
consideration either protein stability or possible increases in
peptide concentration caused by blood cellular excretion or
hemolysis. For example, even if clotting is inhibited by EDTA,
platelets are activated under certain conditions in EDTA tubes,
excreting specific peptides and proteins.27,28 Therefore, caution
is warranted to extrapolate our quorum-sensing peptide
findings to peptides also intracellularly present in blood cells.
We did not find analytical matrix effects caused by the
protease/peptidase inhibitors present in the plasma-sampling
tubes (Figure S1). Nevertheless, the general caution for
interference was applied as recommended when using data-
dependent acquisition in peptidomics. Additionally, no time-
trend in matrix effects was noticed (Figure S2). This confirms
Figure 1. Example LC−MS chromatograms of (A) Q076, (B) Q164, (C) Q176, (D) Q175, and (E) Q019.
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that the noticed decrease in analytical LC−MS peptide
response was due to degradation and not by changes in the
matrix effect.
2.1. Blood Collection. The half-lives for the five peptides
(Table 5) of the training set in the different blood collection
tubes at different temperatures are shown in Table 1. The
calculated half-lives (T50) exceed twice the time period under
investigation. Therefore, the T90 values, the time where 90% of
the peptide is still present (=10% degradation), were used as
more representative for bioanalytical peptidomics. Figure 2
graphically shows the T90 results, with paired Tukey’s multiple
comparisons test conducted on the pooled results to detect
statistically significant differences between the different tubes
at each temperature. Our study aims to find the optimal
Table 1. Half-Lives (Hours) in Whole Blood for the Five Peptides of the Training Set (±SEM)a
half-lives (T50 ± SEM)
peptide temperature (°C) P100 P800 EDTA+ EDTA
Q019 4 49.8 h ± 13.6 29.1 h ± 5.6 9.9 h ± 1.0 3.3 h ± 0.2
21 7.4 h ± 2.2 13.1 h ± 3.3 2.1 h ± 0.2 2.5 h ± 0.5
37 5.9 h ± 1.4 5.8 h ± 0.8 3.2 h ± 0.9 4.3 h ± 0.4
Q076 4 36.7 h ± 5.6 7.6 h ± 1.1 14.9 h ± 4.4 4.1 h ± 0.4
21 3.9 h ± 0.8 6.1 h ± 0.2 3.3 h ± 0.3 1.9 h ± 0.3
37 2.5 h ± 0.3 3.8 h ± 0.4 4.1 h ± 1.7 2.8 h ± 0.3
Q164 4 12.4 h ± 2.3 9.2 h ± 2.3 3.3 h ± 0.3 2.5 h ± 0.2
21 3.5 h ± 0.5 6.8 h ± 0.5 3.8 h ± 0.6 1.3 h ± 0.2
37 3.0 h ± 0.1 6.9 h ± 1.2 3.3 h ± 1.7 4.7 h ± 0.5
Q176 4 24.2 h ± 7.9 6.8 h ± 0.8 7.7 h ± 2.6 9.2 h ± 2.1
21 6.9 h ± 2.2 16.7 h ± 2.2 6.6 h ± 1.3 8.2 h ± 1.8
37 9.0 h ± 2.4 5.6 h ± 0.8 5.8 h ± 0.7 20.2 h ± 6.3
Q184 4 n.a. n.a. n.a. n.a.
21 n.a. n.a. n.a. n.a.
37 33.1 h ± 9.9 29.4 h ± 10.0 77.5 h ± 66.4 23.5 h ± 2.4
an.a., not applicable; no degradation of the peptide was seen within 7.5 h, i.e., the 95% confidence interval of λ includes zero.
Figure 2. T90 values (±SEM; n = 4) at different temperatures for the blood collection tubes. Left, per peptide. Right, per type of blood collection
tube (average of all peptides together), with p-values indicated.
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sampling and storage methods for a broad spectrum of
quorum-sensing peptides. This implies that we are investigat-
ing the “largest common denominator” for blood peptide
identification/quantitation and not an optimal method for each
peptide individually.
The paired Tukey’s multiple-comparison one-way analysis of
variance (ANOVA) showed that at 4 °C, the P100 tube
performed significantly better than the EDTA tube with the
protease inhibitor (EDTA+) (p = 0.024) and the traditional
EDTA tube (p = 0.009). Compared to the P800 tube, P100
almost doubled the stability of the peptides at 4 °C. Although
this effect did not reach statistical significance (p = 0.069), the
standardized mean difference (= Cohen’s d value) between
P100 and P800 tubes at 4 °C was 1.3. Cohen’s d values above
0.8 are generally considered to indicate relevant effect sizes.29
The results also showed that P100 tubes at 4 °C were superior
to all other tested conditions, with half-lives of 12 h and longer.
Q184 was the most stable peptide of the five investigated
peptides, with no degradation of the peptide during the time
frame of 7.5 h at both 4 and 21 °C. The finding of an increased
peptide stability at 4 °C compared to 21 and 37 °C was also
noticed in the non-P100 tubes, although statistically not
significant (Figure S3). This confirms other plasma peptidomic
studies.18
At 21 °C, P800 tubes showed an improved stability
compared to P100 tubes (p = 0.032), EDTA tubes (p =
0.008), and EDTA + tubes (p = 0.005). This is in line with the
study of Yi et al., where the stability of four plasma hormone
peptides was analyzed in classical EDTA tubes, serum tubes,
P700 tubes (not on the market anymore), and P800 tubes at
room temperature.17 A discrepancy was seen in absolute values
of the half-lives between our study and the study of Yi et al.
While some of our peptides had half-lives shorter than 6 h, all
of their peptides investigated had half-lives larger than 45 h
using P800 tubes. However, their peptides did not cover a wide
range of the chemical space, which could explain the T50
discrepancy. Moreover, some or all of their samples underwent
a freeze−thaw cycle (“frozen immediately at −80 °C until later
usage”). Multiple studies have proven a significant decrease in
enzyme activity after freeze−thaw cycles.30,31 A decreased
protease activity after a freeze−thaw cycle could therefore be
the reason for the very long T50 values in the study of Yi et al.
In a separate study, the same group also compared P100 tubes
with EDTA tubes at room temperature, finding an increased
peptide stability for P100 tubes.15 Other studies comparing
P100 tubes vs EDTA tubes however did not find a consistent
peptide/protein stability benefit of the P100 tubes at room
temperature.28,32−35 In our study, there was a small mean
stability benefit of P100 tubes compared to EDTA(+) tubes at
21 °C (Figure 2). However, because of the inconsistency
between the different peptides, this effect did not reach
statistical significance.
The stability of the peptides at 37 °C was evaluated in all
tubes. This is the initial temperature of blood at the moment of
blood withdrawal. No significant differences were measured
between the different tubes for all peptides. Although cooling
freshly drawn blood to 4 °C can be done in a short time,
inevitably there is a phase after withdrawal where the blood has
a temperature between 4 and 37 °C. In that respect, the
minimal half-lives of the peptides of 2.5 h at 37 °C are
reassuring.
Based on the results of the training experiment, a validation
experiment was conducted where the stability of four peptides,
not included in the training experiment, was investigated at 4
°C in P100 tubes. These peptides were chosen from the two
chemical clusters furthest apart from each other (two peptides
from each cluster).21 The slopes of these curves (λ), T50 and
T90 values, are presented in Table 2. The long peptide half-life
of >8 h, determined during the training experiment, was no
longer applicable for two of the four peptides during the
external validation. The two peptides that showed a lowered
stability, i.e., Q054 and Q055, are almost identical, explaining
the identical T50 and suggesting a similar degradation
mechanism.
A head-to-head comparison between P100 at 4 °C and
EDTA at 4 °C was carried out to determine the gain in stability
of Q055 when using a P100 sampling tube stored at 4 °C. The
results are presented in Table 3, and although it was
statistically nonsignificant, an increase in stability was noticed
when using a P100 sampling tube.
2.2. Plasma Storage. To investigate the long-term stability
of peptides in plasma of P100 tubes, plasma collected from
P100 tubes was spiked with the same peptide mix as in the
blood collection training experiment. Table 4 shows the T90
values of the five peptides in plasma when stored at one of the
three different long-term storage temperatures and thawed
once. In line with expectations, maintaining the plasma
samples at low temperatures slowed down the rate of peptide
degradation (Figure 3). After 1 month of storage at −80 °C,
Q164 and Q176 still contained more than 95% of their original
content. However, assuming that the same change in pattern
will continue beyond the period covered by long-term data, T90
values were obtained by extrapolation. It was surprising that
some peptides had very low stabilities, even at −80 °C. Q184,
a relatively hydrophobic small peptide, showed a decrease of
10% degradation after only 2.6 days of storage at −80 °C. After
1 month of storage at this low temperature, only ±25% of the
peptide could be detected. This decrease could be caused by
chemical degradation or other physical forces (e.g., adsorp-
tion).
These findings contrast the common thoughts, in both
clinical and research settings, that long-term plasma storage at
−80 °C does not influence the stability of analytes. As
mentioned above, many peptidomic studies store their samples
at −80 °C, without taking into account the chemical/physical
stability at this temperature. Our results emphasize that this is
Table 2. Decay Constants, T50 and T90 [±SEM], of the Four
QSPs Used for the External Validation
peptide decay constant (λ) T50 (h) T90 (h)
Q044 −0.00126 [±0.00025] 9.15 [±1.84] 1.39 [±0.28]
Q051 −0.00045 [±0.00061] 25.69 [±34.7] 3.91 [±5.28]
Q054 −0.00619 [±0.00056] 1.87 [±0.17] 0.28 [±0.03]
Q055 −0.00776 [±0.00064] 1.49 [±0.12] 0.23 [±0.02]
Table 3. Decay Constants, T50 and T90 [±SEM], of Q055 in
a P100 or an EDTA Sampling Tube
sampling tube decay constant (λ) T50 (h) T90 (h)
EDTA at 4 °C −0.00856 [±0.00210] 1.35 [±0.33] 0.21 [±0.05]
P100 at 4 °C −0.00559 [±0.00098] 2.07 [±0.36]a 0.31 [±0.05]a
aThe obtained results are similar to the results obtained in Table 3,
supporting the consistency of our experiments.
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a false assumption and that storage stability data for
investigated peptides are needed if plasma is stored longer-
term before being analyzed.
2.3. Cost Considerations. Based on the effectiveness
experiments described above, P100 or P800 tubes are preferred
above conventional EDTA tubes for quorum-sensing peptide
analysis. However, when deciding on therapeutic or diagnostic
tools, also costs are important to consider. The BD P100 and
BD P800 tubes currently on the market are available for
around 17−25€ each, while conventional EDTA tubes cost
around 0.4−0.5€ each, i.e., P100 and P800 tubes are about
thirty to sixty times more expensive than the conventional
EDTA tubes. In the case of P100 tubes at 4 °C, this price
difference comes with a mean T50 and T90 increase of 25 and
3.5 h, respectively (Table 1 and Figure 2). Depending on the
purpose of the peptidome identification/quantitation, this cost
increase may or may not be justified. In situations where one
seeks to perform high-throughput experiments and/or
identification/quantitation of high abundant peptides, conven-
tional EDTA tubes may be fit-for-purpose. However, for
detection/quantitation of low abundant peptides or small
peptide concentration differences in a limited set of samples,
the gain in peptidomic sensitivity of P100 tubes seems worth
the extra costs. If, for example, EDTA blood samples are
analyzed 1 h after withdrawal, a significant amount of peptide
degradation will already have occurred (>20% degradation for
a number of peptides). In this situation, low abundant peptides
could fall below the limit of detection, or small peptide
concentration differences could wrongly be attributed to
biological differences (type I errors). Therefore, the choice
of tube should also be based on the purpose of the peptidome
analysis.
3. CONCLUSIONS
Cooling whole blood to 4 °C in BD P100 tubes provides
overall the highest quorum-sensing peptide stability over time
when compared to BD P800 tubes, classical EDTA tubes, and
EDTA tubes supplemented with a protease-inhibitor cocktail
(Sigma-Aldrich) at different temperatures. However, when no
fridge is available and blood samples are forced to be stored at
room temperature (21 °C), the BD P800 collection tubes
prove significantly better than the other tubes. For long-term
plasma storage awaiting its quorum-sensing peptidome
analysis, lower temperatures result in less peptide degradation
over time. However, even at −80 °C, significant degradation
cannot be ruled out. This study should assist researchers and
clinicians in their choice for optimal blood collection and
storage conditions of plasma for quorum-sensing peptidome
analysis.
4. METHODS
4.1. Blood Collection. Healthy adults were enrolled in this
study after providing informed consent according to the
protocol that was approved by the local ethical committee (EC
number B670201734698). The protocol included a training
experiment, followed by a validation experiment. Blood
samples were collected by a medical doctor from the cubital
vein. For the training group, four different tubes were used:
EDTA plasma (Becton Dickinson, product 368861), EDTA
plasma (Becton Dickinson, product 368861) spiked with
protease-inhibitor cocktail (Sigma-Aldrich, product P8340) at
a 1:100 final dilution, BD P100 (Becton Dickinson, product
366448), and BD P800 (Becton Dickinson, product 366421).
In the validation group, only EDTA plasma and BD P100
tubes were used. Immediately after blood withdrawal, the
whole blood was brought to the indicated temperature (during
30 min). Three different temperatures were assessed, namely,
4, 21, and 37 °C. When the desired temperature was reached,
i.e., after 30 min, the whole blood was spiked with the peptide
mix, with each peptide at a final concentration of 10 nM. The
sample preparation and analysis were performed at indicated
timepoints after spiking.
4.2. Plasma Long-Term Storage. Plasma, collected into
BD P100 tubes and separated from blood cells, was spiked with
a peptide mix, with each peptide having a final concentration of
50 nM. The spiked plasma was aliquoted into 500 μL LoBind
Eppendorf tubes (Eppendorf AG, product 022431064) and
stored at three different temperatures, i.e., 4, −35, and −80 °C,
for up to 1 month.
4.3. Quorum-Sensing Peptides. Bacterial quorum-
sensing peptides (QSPs) were used to spike the whole blood
and plasma because they exhibit very diverse chemical
properties.21,36 Previous work conducted by our group defined
different clusters of QSP based on characteristic chemical
properties, including peptide size/compactness, hydrophilic-
ity/lipophilicity, cyclization, and the presence of (unnatural) S-
containing and aromatic amino acids. The QSPs used for the
training (Q019, Q076, Q164, Q176, Q184) and validation
(Q044, Q051, Q054, Q055) experiment were selected from
different clusters, assuring that a reasonably large chemical
space of peptides was involved in the experiments.21 Table 5
Table 4. T90 [±SEM] in P100 Plasma of the Five Peptides
(n = 4)a
peptide temperature (°C) T90 in days (±SEM)
Q019 4 0.21 (±0.03)
−35 4.88 (±0.67)
−80 7.48 (±2.21)
Q076 4 1.24 (±0.03)
−35 20.4 (±13.67)
−80 13.2 (±4.80)
Q164 4 0.95 (±0.23)
−35 33.8 (±45.91)
−80 96.3 (±136.01)
Q176 4 0.48 (±0.02)
−35 16.4 (±6.98)
−80 46.4 (±64.18)
Q184 4 2.24 (±0.20)
−35 2.56 (±0.21)
−80 2.61 (±0.23)
aT90 is extrapolated assuming that the same pattern will continue
beyond the period covered by long-term data.
Figure 3. T90 values (±SEM) at different storage temperatures
(average of all peptides together, n = 4 per peptide).
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indicates the sequences and some physicochemical descriptors
of the peptides, demonstrating their diversity. For the storage
experiment, the same peptides as the training experiment were
used.
4.4. Sample Preparation. For the blood collection
experiments (training and validation samples), the spiked
whole-blood samples were first vortexed. Then, 500 μL
samples were taken after 0, 2.5, 5, and 7.5 h and transferred
to a 1.5 mL LoBind Eppendorf tube (Eppendorf AG, product
022431081). These were centrifuged at 1800g for 10 min at
room temperature (RT). Fifty microliters of the obtained
plasma was transferred to a 0.5 mL Eppendorf coated with an
in-house-developed LC−MS-compatible antiadsorption di-
luent for peptide analysis.37 One hundred fifty microliters of
acetonitrile (Biosolve BV, product 1204102BS) acidified with
0.5% formic acid (Biosolve BV, product 6914143BS) was
added to the plasma, after which the tube was closed. The
samples were subsequently sonicated (5 min at RT), vortexed
(5 s at RT), boiled (30 s at 100 °C), again vortexed (5 s at
RT), and centrifuged at 20 000g for 20 min. Finally, the
samples were put in the sample manager (10 °C) for UPLC−
MS−MS analysis (60 °C). On average, the relative standard
deviation (RSD) for the complete analytical workflow (spiking,
sample preparation, and analytical method) was 19.5%, which
is considered as an acceptable value (EMA and FDA Draft
Guideline on validation of bioanalytical methods).
For the storage experiment, peptide concentrations in
plasma were assessed before storage and after 1, 7, and 30
days of storage. Fifty microliters of the plasma was transferred
to a coated 0.5 mL tube as described above, after which the
same protocol was followed as in the blood collection
experiments.
4.5. Peptide Identification and Quantitation by
UPLC−MS/MS. Chromatographic separation was achieved
on a Waters Acquity UPLC BEH amide column (2.1 mm ×
100 mm; 1.7 μm particles), protected with a guard column. A
mobile phase system consisting of solvent A (water,
acetonitrile, and dimethyl sulfoxide (DMSO) at the ratio of
93:2:5 v/v/v and 0.1% formic acid m/v) and solvent B (water,
acetonitrile, and DMSO in the ratio of 2:93:5 v/v/v and 0.1%
formic acid m/v) with a gradient from 100 to 45% B in 5 min
was applied. DMSO was added as a supercharger and to reduce
carryover.38 The mobile phase was delivered at a flow rate of
0.5 mL/min, with a total run time of 15 min. The UPLC
system was connected to a Xevo TQ-S spectrometer with
electrospray ionization (set in the positive mode). The mass
spectrometric conditions used throughout the analyses as well
as the MRMs of the peptides are shown in Table S1.
4.6. Data Analysis. The areas were normalized to the area
measured at T = 0 (for each tube at different temperatures),
and subsequently, the natural logarithm (n) of each relative
value was calculated. Assuming first-order kinetics, the decay
constant (λ), obtained from the slope of the best-fitting ln-
linear degradation curve, was used to determine the half-life
using the following formula
T
ln(2)
50 λ
= −
The standard error of the mean (SEM) on the half-life (T1/2)
was estimated using the propagation of errors with the
following formula39
T
n
SEM ( )
( )
50
ln(2)
2 σ λ
≃
×λ
with σ(λ) being the standard deviation on the decay constant.
Similar calculations were conducted for the T90, i.e., the time
where still 90% of the initial concentration is present
T
ln
90
10
9
λ
= −
( )
T
n
SEM ( )
( )
90
ln 10
9
2 σ λ
≃
×λ
One-way ANOVA with paired multiple-comparison Tukey’s
test was applied to detect statistical significant differences
between tubes. All statistical analyses were done with
GraphPad Prism Version 6 (San Diego, CA).
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Table 5. Sequences and Some Physicochemical Descriptors of the Quorum-Sensing Peptides Used in This Studya
peptide (supplier) sequence log P pI MW
Q019b NNWNN −7.17 5.29 660.7
Q044c EKMIG −2.57 6.21 576.8
Q051c ERNNT −6.8 6.17 632.7
Q054c ESRLPKIRFDFIFPRKK −3.58 10.84 2178.0
Q055d ESRVSRIILDFLFQRKK −5.44 10.94 2135.9
Q076c SNLVECVFSLFKKCN −6.35 8.41 1731.3
Q164c SDLPFEH −2.84 4.13 844.0
Q176c SGSLSTFFRLFNRSFTQALGK −9.69 11.00 2365.0
Q184c SIFTLVA 0.09 5.71 750.0
aPeptide numbering used in the Quorumpeps database (quorumpeps.ugent.be) is retained in this study. Peptides were synthesized with terminal
free acids by. bJPT Peptide Technologies. cGL Biochem. dProteoGenix. P, octanol−water partition coefficient; pI, isoelectric point; MW, molecular
weight.
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